STOCK TITAN

RCUS insider sale notice: 2,831 RSU shares valued at $36.35k

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sale of 2,831 RSU-derived shares valued at ~$36k; disclosed under Form 144, appears routine and not large.

The filing shows a proposed sale of restricted stock unit shares acquired on 12/15/2024. Execution is through a broker on 09/29/2025, with a recent related 10b5-1 sale of 1,579 shares on 09/05/2025. For investors, these transactions are documented disposals by an insider or related party rather than company-level corporate actions. The sizes and proceeds disclosed are explicit and should be compared to outstanding shares and typical insider activity to assess significance.

TL;DR: Form 144 properly discloses proposed sale and RSU origin; includes required insider certification about material nonpublic information.

The notice includes required details: class of securities, broker, acquisition date and nature (RSUs), and prior sales in the past three months. It also contains the representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption where relevant. Filing completeness supports regulatory compliance for an insider sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Arcus Biosciences (RCUS) disclose?

The form discloses a proposed sale of 2,831 common shares via Morgan Stanley Smith Barney on 09/29/2025 valued at $36,350.04.

How were the shares being sold acquired according to the filing?

The shares were acquired as restricted stock units on 12/15/2024, with the filing listing the acquisition and payment date as 12/15/2024.

Were there any recent related sales reported in the past three months?

Yes. A 10b5-1 sale by Alexander Azoy of 1,579 common shares on 09/05/2025 generated gross proceeds of $18,758.05.

Through which broker will the proposed sale be executed?

The proposed sale is listed to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, NY.

Does the Form 144 include any statement about material nonpublic information?

Yes. The person for whose account the securities will be sold represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Arcus Bioscience

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Latest SEC Filings

RCUS Stock Data

2.70B
84.75M
34.73%
67.52%
9.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD